Caris Life Sciences, Inc. cash flow statement

In fiscal 2025, Caris Life Sciences, Inc.'s operations generated $83.2m of cash; it spent $16.3m on capital projects, leaving free cash flow of $66.9m. It returned $113,000 through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Caris Life Sciences, Inc.: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−276	−245	83	169
Depreciation and amortisation	49	49	23	21
Stock-based pay	15	19	70	65
Capital spending	22	8	16	45
Free cash flow	−298	−254	67	124
Free cash flow after stock pay	−314	−272	−3	59
Share buybacks	0	0	0	21

US$ millions unless shown otherwise. Fiscal quarters.

Caris Life Sciences, Inc.: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−69	−39	−31	7	62	45	33	28
Depreciation and amortisation	11	9	7	6	5	4	5	7
Stock-based pay	5	5	15	28	14	13	16	22
Capital spending	2	2	3	1	7	5	10	22
Free cash flow	−71	−41	−34	6	55	40	23	6
Free cash flow after stock pay	−76	−46	−49	−22	42	26	7	−16

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CAI vs INNV CAI vs CRVL CAI vs PNTG

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Caris Life Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Caris Life Sciences, Inc.